Global Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2019-2024

Description

The Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2019 - 2024 report provides a detailed understanding and analysis of how and why companies enter clinical stage partnering deals and provides details of the latest clinical agreements announced in the healthcare sector.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of over 1,800 clinical stage partnering deals announced since 2016 including financial terms where available including numerous links to online deal records of actual clinical partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of clinical stage deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of why companies partner clinical stage compounds/products.

Chapter 3 provides an overview of clinical stage deals strategy and deal structure including numerous case studies.

Chapter 4 provides an overview of the various payment strategies used in clinical stage deals.

Chapter 5 provides a review of clinical stage deal making since 2019. Deals activity is reviewed by year, stage of development at signing, therapeutic area, technology type, as well as most active dealmakers.

Chapter 6 provides a detailed analysis of clinical stage payment terms including headline, upfront, milestone and royalty rates for phase I, phase II and phase III deals.

Chapter 7 provides a review of the leading clinical stage deal by headline value. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 8 provides a comprehensive listing of the top 25 most active clinical stage dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.

Chapter 9 provides a comprehensive and detailed review of clinical stage partnering deals signed and announced since 2019, where a contract document is available in the public domain.

Chapter 10 provides a comprehensive directory of clinical stage partnering deals since 2019 organized by stage of development - phase I, phase II and phase III.

The report includes numerous tables and figures that illustrate the trends and activities in clinical stage partnering and deal making since 2019.

In addition, a comprehensive appendix of all clinical stage deals since 2019 is provided organized by partnering company A-Z, deal type, therapy focus and technology type. Each deal title links via weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of clinical stage products and compounds.

Key benefits

Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2019 - 2024 provides the reader with the following key benefits:

In-depth understanding of clinical stage deal trends since 2019
Access to headline, upfront, milestone and royalty data
Analysis of the structure of clinical stage agreements with numerous real life case studies
Insight into the terms included in a clinical stage agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2019-2024 is intended to provide the reader with an in-depth understanding and access to clinical stage deal trends and structure of deals entered into by leading companies worldwide.

Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2019-2024 includes:

Trends in clinical stage dealmaking in the biopharma industry since 2019
Analysis of clinical stage deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life clinical stage deals
Access to over 1,800 clinical stage deals
The leading clinical stage deals by value since 2019
Most active clinical stage dealmakers since 2019
The leading clinical stage partnering resources

In Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2019-2024, the available contracts are listed by:

Company A-Z
Headline value
Stage of development at signing
Deal type
Specific therapy target
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The Clinical Stage Partnering Terms and Agreements in Pharma and Biotech 2019-2024 report provides comprehensive access to available deals and contract documents for over 1,800 clinical stage deals. Analyzing actual contract agreements allows assessment of the following:

What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?

Product Code: CP2058

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Why do companies partner clinical stage compounds?

2.1. Introduction
2.2. The role of clinical stage partnering
- 2.2.1. In-licensing at clinical stage
- 2.2.2. Out-licensing at clinical stage
2.3. Difference between phase I, II and III stage deals
2.4. Reasons for entering into clinical stage partnering deals
- 2.4.1. Licensors reasons for entering clinical stage deals
- 2.4.2. Licensees reasons for entering clinical stage deals
2.5. The future of clinical stage partnering deals

Chapter 3 - Clinical stage deal strategies and structure

3.1. Introduction
3.2. At what stage do companies partner?
- 3.2.1. Partnering early in pharmaceutical/biotech
- 3.2.1.1. Discovery and preclinical stage partnering case studies
- 3.2.1.1.a. Case study 1
- 3.2.1.1.b. Case study 2
- 3.2.1.1.c. Case study 3
- 3.2.1.1.d. Case study 4
- 3.2.2. Partnering later in pharmaceutical/biotech
- 3.2.2.1. Clinical stage partnering case studies
- 3.2.2.1.a. Case study 5
- 3.2.2.1.b. Case study 6
- 3.2.2.1.c. Case study 7
- 3.2.2.1.d. Case study 8
3.3. Early and later stage partnering - a risk/cost comparison
3.4. What do companies spend on clinical stage partnering?
3.5. Pure versus multi-component partnering deals
3.6. Pure licensing agreement structure
- 3.6.1. Example pure licensing agreements
- 3.6.1.a. Case study 9
- 3.6.1.b. Case study 10
3.7. Multicomponent clinical stage partnering agreements
- 3.7.1. Example multicomponent clinical stage clauses
- 3.7.1.a. Case study 11

Chapter 4 - Clinical stage partnering payment strategies

4.1. Introduction
4.2. Clinical stage payment strategies
4.3. Payment options
- 4.3.1. Headline values
- 4.3.2. Upfront payments
- 4.3.2.1. Conditionality of upfront payments
- 4.3.3. Loans
- 4.3.4. Convertible loans
- 4.3.5. Equity
- 4.3.6. R&D funding
- 4.3.7. Licensing fees
- 4.3.8. Milestone payments
- 4.3.9. Royalty payments
- 4.3.9.1. Issues affecting royalty rates
- 4.3.9.2. Royalties on combination products
- 4.3.9.2.a. Case study 12
- 4.3.9.3. Guaranteed minimum/maximum annual payments
- 4.3.9.4. Royalty stacking
- 4.3.9.5. Royalties and supply/purchase contracts
- 4.3.10. Quids
- 4.3.11. Option payments

Chapter 5 - Trends in clinical stage deal making

5.1. Introduction
5.2. Clinical stage partnering over the years
- 5.2.1. Trends in phase I deals since 2019
- 5.2.1.1. Attributes of phase I deals
- 5.2.2. Trends in phase II deals since 2019
- 5.2.2.2. Attributes of phase II deals
- 5.2.3. Trends in phase III deals since 2019
- 5.2.3.1. Attributes of phase III deals
5.3. Clinical stage partnering by deal type
5.4. Clinical stage partnering by disease type
5.5. Partnering by clinical stage technology type
5.6. Clinical stage partnering by most active company since 2016

Chapter 6 - Payment terms for clinical stage partnering

6.1. Introduction
6.2. Guidelines for clinical stage payment terms
- 6.2.1. Upfront payments
- 6.2.2. Milestone payments
- 6.2.3. Royalty payments
6.3. Clinical stage payment terms - deal data analysis
- 6.3.1. Public data
- 6.3.2. Survey data
6.4. Payment terms analysis
- 6.4.1. Clinical stage partnering headline values
- 6.4.2. Clinical stage deal upfront payments
- 6.4.3. Clinical stage deal milestone payments
- 6.4.4. Clinical stage royalty rates
6.5 Clinical stage median financials
- 6.5.1. Clinical stage headline value
- 6.5.2. Clinical stage upfront value
- 6.5.3. Clinical stage milestone value
- 6.5.4. Clinical stage royalty value

Chapter 7 - Leading clinical stage deals

7.1. Introduction
7.2. Top clinical stage deals by value

Chapter 8 - Top 25 most active clinical stage dealmakers

8.1. Introduction
8.2. Top 25 most active clinical stage dealmakers

Chapter 9 - Clinical stage partnering contracts directory

9.1. Introduction
9.2. Clinical stage deals with contracts since 2016

Chapter 10 - Clinical stage deal making by development stage

10.1. Introduction
10.2. Deals by clinical stage
Phase I
Phase II
Phase III
Regulatory

Appendices

Appendix 1 - Clinical stage dealmaking by companies A-Z
Appendix 2 - Clinical stage dealmaking by industry sector
Appendix 3 - Clinical stage dealmaking by stage of development
Appendix 4 - Clinical stage dealmaking by therapy area
Appendix 5 - Clinical stage dealmaking by technology type

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering

Table of figures

Figure 1: Definition of clinical phases in dealmaking
Figure 2: Components of the pure licensing deal structure
Figure 3: Payment options for clinical stage partnering deals
Figure 4: Issues affecting royalty rates
Figure 5: Clinical stage partnering by deal type since 2019
Figure 6: Clinical stage partnering by disease type since 2019
Figure 7: Clinical stage partnering by technology type since 2019
Figure 8: Top 25 most active clinical stage dealmakers, 2019 - 2024
Figure 9: Review of upfront payments for clinical stage deals
Figure 10: Review of milestone payments for clinical stage deals
Figure 11: Review of royalty payments for clinical stage deals
Figure 12: Clinical stage deals with a headline value
Figure 13: Clinical stage deals with an upfront value
Figure 14: Clinical stage deals with a milestone value
Figure 15: Clinical stage deals with a royalty rate value
Figure 16: Top clinical stage deals by value since 2019
Figure 17: Most active clinical stage dealmakers 2019 - 2024